[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiac-ischemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiac-ischemia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100588836","phase-4-cardiac-changes-after-effective-dose-carbetocin-for-elective-caesarian-section-100588836",false,"NCT06946589","Cardiac Changes After Effective Dose Carbetocin for Elective Caesarian Section","Inclusion Criteria:\n\n* Undergoing elective cesarian section\n* Primary and repeat cesarian section\n\nExclusion Criteria:\n\n* Prior and current cardiovascular co-morbidities including pre-eclampsia\n* BMI greater than 50\n* Pre-existing bleeding disorders\n* Allergy to carbetocin\n* Age under 18","FEMALE","18 Years",{"count":18,"type":19},200,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","The goal of this project is to examine the cardiac symptoms and physiologic changes after administration of a reduced dose of carbetocin in participants undergoing elective cesarian section.\n\n* Does reduced dose carbetocin (50mcg) have fewer cardiac side effects than usual dose carbetocin (100mcg) when comparing patient reported symptoms, ECG changes and troponin increases?\n* Is there a relationship between patient reported cardiac symptoms after carbetocin administration and subjective measures of cardiac ischemia (ECG changes and troponin increases? Researchers will compare 50mcg of carbetocin to the control group of 100mcg of carbetocin in patients undergoing elective cesarian section.\n\nParticipants will:\n\n* Be given 50mcg or 100mcg of carbetocin during cesarian section\n* Asked to report cardiac symptoms\n* Be assessed for ECG changes and blood loss using standard of practice monitoring\n* Have a troponin I blood test completed after delivery",[25,26],"Cardiac Ischemia","Cesarian Section",[28,29,30],"carbetocin","duratocin","cardiac symptoms","NOT_YET_RECRUITING","2025-04-20",{"date":34,"type":35},"2025-04-27","ACTUAL",{"date":37,"type":19},"2025-08-01",{"date":39,"type":19},"2027-09-01",{"name":41,"class":42},"Jordan Leitch","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":43},"100587626","frailty-classification-algorithm-for-the-corsano-cardiowatch-287-2-a-development-and-validation-study-100587626","NCT06930833","FRAILTY Classification Algorithm for the Corsano CARDIOWATCH 287-2: a Development and Validation Study","FRAILTY-CW2","Inclusion Criteria:\n\n* ≥ 70 years old\n* Be able to provide consent\n* Be scheduled to undergo one of the following procedures:\n\n  * Aortic valve replacement\n  * Mitral valve repair with MitraClip\n  * Implantation of a pacemaker\n  * Percutaneous coronary intervention (PCI)\n\nExclusion Criteria:\n\n* Unable to wear the Corsano CardioWatch 287-2 due to reasons such as allergic reactions, wounds, amputations etc.;\n* Unable or unwilling to sign informed consent;\n* Significant mental or cognitive impairment;\n* Cardiovascular disease where heart rate is not measurable (e.g. LVAD)","ALL","70 Years",{"count":54,"type":19},20,"OBSERVATIONAL","The FRAILTY-CARDIOWATCH study is investigating how well the Corsano CardioWatch 287-2, a wrist-worn medical device, can classify frailty in patients. Frailty is a condition often seen in older adults, characterized by decreased strength, endurance, and overall health, which can make individuals more vulnerable to illness or injury. The goal of this study is to develop an algorithm that can accurately assess frailty using the device. In phase 1 of the study, data will be collected from patients aged 70 or older who are scheduled for heart-related procedures, such as valve replacements or pacemaker implantation.\n\nThe study aims to compare the frailty classifications of the CardioWatch with two established methods: the Geriatric 8 (G8) questionnaire and the FRAIL scale. It will also compare the CardioWatch with the 6-minute walk test. Patients will wear the CardioWatch for six days-three days before their procedure and three days after-and complete the G8, FRAIL, and 6-minute walk tests. The collected data will help develop and train the frailty classification algorithm.\n\nThe main focus is to evaluate how well the frailty classifications from the CardioWatch match those from the other tests. This research could potentially lead to a more accurate and continuous way to monitor frailty in patients using wearable technology.",[58,59,25],"Cardiac Arrythmias","Valve Heart Disease",[61,62,63,64,65,66,67],"Frailty","6-minute walking test","G8-score","wristband","wearable","remote monitoring","cardiac surgical interventions","2025-04-16",{"date":32,"type":35},{"date":71,"type":19},"2025-05",{"date":73,"type":19},"2026-10",{"name":75,"class":76},"Corsano Health B.V.","INDUSTRY"]